While I appreciate your response, you're effectively saying that you're comfortable with how IMU is progressing PD1-VAXX because of what a now ex-employee has told you...
The data you're referring would appear to be the preclinical model work on PD1-VAXX produced by Ohio State Uni.
And just to re-state my position on PD1-VAXX again - I think the 25% CR rate in cohort 1 (i.e. 1/10 the dose of the final cohort 3 which achieved 0 CRs) of the Imprinter trial was very interesting and I think IMU may have dropped the ball on this one (this was produced as a result of a single agent PD1-VAXX regime). This is why I'd like to understand the dose regime for NeoPOLEM.
However, this doesn't address the elephant in the room:
P.S. Still no idea how much this will cost IMU with maybe $20m cash on hand...
IMU Price at posting:
1.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)